Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma
- PMID: 16570180
- DOI: 10.1007/s00428-006-0183-8
Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma
Abstract
Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumors, while in a limited number of neoplasms, E-cadherin is re-expressed in metastases. Dysadherin, recently characterized by members of our research team, has an anti-cell-cell adhesion function and downregulates E-cadherin in a posttranscriptional manner. Colorectal cancer (CRC) is one of the most common tumors in the developed world, and lymph node metastases are harbingers of aggressive behavior. The aim of the present study was to examine the dysadherin and E-cadherin expression patterns in lymph node metastases vs primary CRC. Dysadherin and E-cadherin expression was examined immunohistochemically in 78 patients with CRC, Dukes' stage C in the primary tumor and in one lymph node metastasis. Dysadherin was expressed in 42% while E-cadherin immunoreactivity was reduced in 45% of primary tumors. In lymph nodes, 33 and 81% of metastatic tumors were positive for dysadherin and E-cadherin, respectively. Dysadherin expression was not correlated with E-cadherin expression in the primary tumor with a reverse correlation evident in the lymph node metastases. Our results suggest that different mechanisms govern E-cadherin expression in the primary tumor and the corresponding lymph node metastases.
Similar articles
-
Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer.Med Oncol. 2012 Sep;29(3):1463-7. doi: 10.1007/s12032-011-0118-3. Epub 2011 Nov 22. Med Oncol. 2012. PMID: 22105147 Review.
-
Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.Cancer. 2005 Apr 15;103(8):1693-700. doi: 10.1002/cncr.20984. Cancer. 2005. PMID: 15751018
-
Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.J Clin Oncol. 2003 Feb 15;21(4):659-67. doi: 10.1200/JCO.2003.06.179. J Clin Oncol. 2003. PMID: 12586803
-
In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.Br J Cancer. 2007 May 7;96(9):1404-8. doi: 10.1038/sj.bjc.6603743. Epub 2007 Apr 17. Br J Cancer. 2007. PMID: 17437014 Free PMC article.
-
Adhesion molecules in cancer of the head and neck: role of dysadherin.J BUON. 2011 Oct-Dec;16(4):609-12. J BUON. 2011. PMID: 22331710 Review.
Cited by
-
Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.Oncogene. 2014 Jan 9;33(2):225-35. doi: 10.1038/onc.2012.563. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318419 Free PMC article.
-
Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer.Exp Ther Med. 2010 May;1(3):457-462. doi: 10.3892/etm_00000071. Epub 2010 May 1. Exp Ther Med. 2010. PMID: 22993562 Free PMC article.
-
Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer.Med Oncol. 2012 Sep;29(3):1463-7. doi: 10.1007/s12032-011-0118-3. Epub 2011 Nov 22. Med Oncol. 2012. PMID: 22105147 Review.
-
An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.Pathol Oncol Res. 2009 Dec;15(4):579-87. doi: 10.1007/s12253-009-9157-x. Epub 2009 Mar 1. Pathol Oncol Res. 2009. PMID: 19253033
-
Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.Future Sci OA. 2025 Dec;11(1):2494972. doi: 10.1080/20565623.2025.2494972. Epub 2025 Apr 28. Future Sci OA. 2025. PMID: 40292544 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical